News

Ciclosporin 0.1% eye drops solution will be marketed under the brand name Vevizye in the EU for the treatment of dry eye disease.

Because the inner retinal function is thought to affect the emmetropization process, authors suggested that caffeine may be involved in ocular growth

The company’s flagship product is Reti-CVD, an AI diagnostic solution that autonomously assesses future cardiovascular disease risk using a retina scan.

The TECNIS Odyssey IOL is a new full vision range IOL built on the TECNIS platform.

Clobetasol is FDA-approved for the treatment of post-operative inflammation and pain following ocular surgery.

Published data from a pair of Phase 3 clinical trials demonstrated a reversal of pharmacologically-induced mydriasis with a favorable safety profile.

Lloyd Clark, MD, discusses the evolution and current practices in the treatment of common retinal diseases such as age-related macular degeneration, diabetic macular edema, and retinal vein occlusion.

At EyeCon 2024, Analisa Arosemena, MD, discussed the shift away from traditional topical therapies towards more proactive management techniques, aiming to enhance patient outcomes in glaucoma care.

A collaborative model not only enhances the post-cataract experience but also paves the way for a future where refractive outcomes are accessible to all, regardless of the surgeon's specialty.

Three resident eye care providers—Anupam Garg, MD, PhD; Khanh Huang, OD; and Shail Patel, MD—were honored with the Visionary in Eye Care award at EyeCon 2024, which recognizes their achievements and contributions during their residency programs.

Adam S. Wenick, MD, PhD, discussed myopia interventions across the lifespan at EyeCon 2024, covering treatments, complications, and prevention strategies.

David Chin Yee, MD, sat down with Ophthalmology Times to discuss his presentation on what every Optometrist and Ophthalmologist should know about geographic atrophy at Eyecon 2024.

Adam S. Wenick, MD, PhD, chaired a symposium on geographic atrophy (GA) at EyeCon 2024, focusing on the diagnosis, monitoring, and FDA-approved treatments for GA. The session with Leonard Messner, OD, FAAO, also included case presentations that highlighted key factors for clinicians to consider when selecting appropriate treatment options.

In a study, a team of Chinese researchers looked at the mechanisms behind the development of EI and explored effective treatment options.

Optometry cochairs Kelly K. Nichols, OD, MPH, PhD, FAAO, and A. Paul Chous, OD, MA, FAAO, highlight the conference’s focus on collaboration, featuring topics like red flags for patient care, thyroid eye disease, and diabetes management.

This Week in Ophthalmology is a video series highlighting some of the top articles featured on the Ophthalmology Times website.

Peter J. McDonnell, MD, and Laura M. Periman, MD, discuss recent innovations in ophthalmology, emphasizing ocular surface disease and the growing complexity of care at EyeCon 2024, held September 27 and 28, in Fort Lauderdale, Florida.

Wendy Lee, MD, sat down with Ophthalmology Times to discuss a symposium she participated in at Eyecon 2024 focusing on Thyroid Eye Disease.

The NIH-supported findings could pave the way for genetic testing, clinical trials, and therapy development for these diseases.

Evaluando los beneficios de un paquete de expansión, sus costos y riesgos asociados

Sumit Sharma, MD, sat down with Sydney Crago of Modern Retina to discuss his presentation on the 3 tyrosine kinase inhibitors currently in development for the treatment of retina conditions at the Retina Society meeting being held this year in Lisbon, Portugal.

This research builds on previous experience that stimulating nicotinic receptors can inhibit experimental myopia

Additionally, FDA grants Fast Track Designation to brepocitinib for non-infectious uveitis.

The agency confirmed its June 2024 negative opinion after Apellis requested re-examination of EMA's initial opinion.

Vyznova is for the treatment of bullous keratopathy of the cornea, a sight-threatening and debilitating condition affecting the endothelial cells of the cornea.

TEPEZZA is the first and only medicine approved in Japan to treat active TED.

Presented by the National Center for Children’s Vision and Eye Health at Prevent Blindness, the Bonnie Strickland Champion for Children’s Vision Award recognizes efforts by an individual or group of individuals, to improve public health approaches for children’s vision and eye health.